Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cevostamab in Systemic Lupus Erythematosus With or Without Lupus Nephritis
NCT07629583Phase 1Recruiting
- Sponsor
- Genentech
- Start
- Nov 2026
- Primary completion
- Mar 2030
- Countries
- 6
01
Overview
Phase 1, open-label, single-arm trial of cevostamab in systemic lupus erythematosus (SLE) and lupus nephritis (LN), sponsored by Genentech. Primary endpoint: Percentage of Participants with Adverse Events at 52 weeks. Started Nov 2026; status: recruiting.
02
Drugs
cevostamab
03
Conditions
systemic lupus erythematosus (SLE)lupus nephritis (LN)
Beyond the preview
Go deeper on NCT07629583.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07629583.